SMFR

Sema4 Holdings Corp., known in the market as Sema4, functions as a health information enterprise committed to leveraging data to enhance the diagnosis, treatment, and prevention of illnesses. A primary offering is Centrellis, an AI-driven health intelligence platform that furnishes extensive insights to biopharmaceutical firms, thereby streamlining the entire lifecycle of drug discovery, development, and commercialization. Centrellis further provides practical analytics, assistance for pre-clinical and clinical trials, and state-of-the-art sequencing capabilities. The company also markets Sema4 Signal, a product designed to facilitate and advance precise oncology care, covering everything from prevention strategies to active treatment and managing remission. Additionally, their diagnostic services encompass carrier screening, non-invasive prenatal assessments, newborn screening, and hereditary cancer testing, complemented by their COVID-19 testing solutions. Sema4 Holdings Corp. was established in 2020 and is based in Stamford, Connecticut.